Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
- Conditions
- Sarcoma
- Interventions
- Procedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 38
- Registration Number
- NCT00061893
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States
Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 400
- Registration Number
- NCT00002822
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
Stem Cell Transplant to Treat Patients With Systemic Sclerosis
- Conditions
- Systemic Sclerosis
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT00058578
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
- Conditions
- LEUKEMIA
- Interventions
- Drug: Anti-CD45Radiation: Total Body Irradiation
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT00057005
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00006260
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Procedure: bone marrow ablation with stem cell supportProcedure: peripheral blood stem cell transplantationProcedure: conventional surgery
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT00003042
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
- Conditions
- Central Nervous System TumorBrain Tumor
- Interventions
- Radiation: radiation therapyBiological: filgrastimProcedure: therapeutic conventional surgery
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 378
- Registration Number
- NCT00027846
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Procedure: autologous bone marrow transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Target Recruit Count
- 27
- Registration Number
- NCT00006373
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Procedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 69
- Registration Number
- NCT00002941
- Locations
- 🇺🇸
All Children's Hospital, St. Petersburg, Florida, United States
🇺🇸Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
🇺🇸Children's Hospital Central California, Madera, California, United States
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
- Conditions
- Cancer
- Interventions
- Biological: filgrastimProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT00002854
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.